



SITUATION REPORT

Nigeria Centre For Disease Control (NCDC)

NCDC.GOV.NG

PLOT 800 EBITU UKIWE STREET, JABI ABUJA, NIGERIA TOLL FREE CALL: 6232 E:info@ncdc.gov.ng

@NCDCgov



| | |
|-----------------------|--|
| TITLE: | UPDATE ON MPOX (MPX) IN NIGERIA |
| SERIAL NUMBER: | 50 |
| EPI-WEEK: | 50 |
| DATE: | December 17, 2023 |

Table 1 – Key Indicators

| Reporting Year | Reporting week | Suspected cases | Confirmed cases | Deaths (Confirmed cases) | Case Fatality Ratio (CFR) | States Affected (Confirmed cases) | LGAs Affected (Confirmed cases) |
|-----------------|----------------|-----------------|-----------------|--------------------------|---------------------------|-----------------------------------|---------------------------------|
| 2023 Current | Week 50 | 21 | 2 | 0 | 0.0 | 2 | 2 |
| 2023 Cumulative | Week 50 | 1175 | 97 | 2 | 2.1 | 24 +FCT | 64 |
| 2022 Cumulative | Week 50 | 2039 | 752 | 7 | 1.0 | 34 + FCT | 236 |

Highlights

- In week 50, the number of new suspected cases is 21, compared with 23 cases reported in week 49, 2023. These were reported from eleven (11) States – Ogun (5), Enugu (5), Ekiti (2), Abia (2), Edo (1), Delta (1), Nasarawa (1), Bayelsa (1), Ondo (1), Cross River (1) and Gombe (1) across 14 Local Government Areas.
- Since week 1 of 2023, twenty-four (24) States and FCT have recorded at least one confirmed Mpox case across sixty-two (62) Local Government Areas. In 2023, the States with the highest burden are Lagos (28.6%), Ogun (18.7%), Abia (6.6%), Imo and (6.0%) and Edo (6.0%), contributing 64.8% of confirmed cases.
- The number of confirmed cases is two (2) in week 50, 2023, compared with zero (0) confirmed case reported in week 49, 2023.
- No death was recorded in week 50, with a CFR of 0.0% same as CFR of 0.0% that was reported in week 49, 2023.
- Overall, since the re-emergence of Mpox in September 2017, 3764 suspected cases have been reported from 36 States and FCT in the country. Of these 3764 suspected cases, 1085 (28.8%) were confirmed (with males predominantly affected) from 34 States and FCT. seventeen (17) deaths have been recorded since the re-emergence in 2017.
- The National Mpox multi-partner, multi-sectoral Technical Working Group (TWG) continues to coordinate the response activities at all levels.






Figure 1: Epidemic curve of suspected and confirmed Mpox cases January 2023 till date.




Figure 2: Age and sex distribution of Nigeria confirmed monkeypox cases from January 2023 till date.




Figure 3: Map of Nigeria showing States with suspected and confirmed Mpox Cases from January 2023 till date.




Figure 4: Nigeria confirmed Mpox cases by the year of incidence- September 2017 to 17th December 2023.

Table 1: Summary statistics for annual Nigeria Mpox cases by reporting year, September 2017 – 17th December 2023

| Reporting year | Suspected cases | Confirmed cases | Deaths (Confirmed cases) | Case Fatality Ratio (CFR) | States Affected (Confirmed cases) | LGAs Affected (Confirmed cases) |
|----------------|-----------------|-----------------|--------------------------|---------------------------|-----------------------------------|---------------------------------|
| 2023 | 1175 | 97 | 2 | 2.1 | 24 +FCT | 62 |
| 2022 | 2123 | 762 | 7 | 0.9 | 34 + FCT | 238 |
| 2021 | 98 | 34 | 0 | 0.0 | 8 + FCT | 25 |
| 2020 | 35 | 8 | 0 | 0.0 | 5 | 7 |
| 2019 | 65 | 47 | 1 | 2.1 | 11 | 26 |
| 2018 | 116 | 49 | 1 | 2.0 | 13 | 25 |
| 2017 | 198 | 88 | 6 | 6.8 | 14 + FCT | 33 |

Table 2: Age distribution of cumulative number of confirmed Mpox cases September 2017 – 17th December 2023

| Age Group | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Total |
|--------------|-----------|-----------|-----------|----------|-----------|------------|-----------|-------------|
| 0-10 Years | 7 | 5 | 1 | 0 | 1 | 125 | 21 | 160 |
| 11-20 Years | 12 | 4 | 1 | 0 | 4 | 123 | 8 | 152 |
| 21-30 Years | 34 | 13 | 13 | 4 | 10 | 187 | 24 | 285 |
| 31- 40 Years | 26 | 17 | 22 | 4 | 13 | 205 | 21 | 308 |
| 41-50 Years | 9 | 10 | 9 | 0 | 5 | 89 | 17 | 139 |
| > 50 Years | 0 | 0 | 1 | 0 | 1 | 33 | 6 | 41 |
| Total | 88 | 49 | 47 | 8 | 34 | 762 | 97 | 1085 |

Table 3: Nigeria confirmed Mpox cases by State, September 2017 – 17th December 2023

| S/N | State | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Total |
|-----|-------------|------|------|------|------|------|------|------|-------|
| 1 | Lagos | 4 | 1 | 15 | 4 | 6 | 188 | 27 | 245 |
| 2 | Rivers | 25 | 14 | 7 | 1 | 5 | 37 | 4 | 93 |
| 3 | Bayelsa | 19 | 11 | 7 | 0 | 6 | 45 | 2 | 90 |
| 4 | Abia | 1 | 2 | 0 | 0 | 0 | 58 | 6 | 67 |
| 5 | Delta | 3 | 6 | 10 | 1 | 9 | 31 | 2 | 62 |
| 6 | Imo | 5 | 2 | 1 | 0 | 0 | 45 | 5 | 58 |
| 7 | Ogun | 0 | 0 | 0 | 0 | 1 | 40 | 17 | 58 |
| 8 | Ondo | 0 | 0 | 0 | 0 | 0 | 40 | 2 | 42 |
| 9 | Edo | 4 | 1 | 1 | 0 | 4 | 27 | 4 | 41 |
| 10 | FCT | 5 | 0 | 0 | 0 | 1 | 25 | 4 | 35 |
| 11 | Anambra | 0 | 1 | 1 | 0 | 0 | 25 | 0 | 27 |
| 12 | Cross River | 9 | 3 | 1 | 0 | 1 | 12 | 1 | 27 |
| 13 | Kwara | 0 | 0 | 0 | 0 | 0 | 21 | 0 | 21 |
| 14 | Plateau | 0 | 2 | 0 | 1 | 0 | 16 | 0 | 19 |
| 15 | Akwa Ibom | 6 | 0 | 1 | 0 | 0 | 12 | 4 | 23 |
| 16 | Nasarawa | 1 | 1 | 0 | 0 | 0 | 17 | 1 | 20 |
| 17 | Adamawa | 0 | 0 | 0 | 0 | 0 | 16 | 0 | 16 |
| 18 | Oyo | 1 | 3 | 2 | 0 | 0 | 10 | 1 | 17 |
| 19 | Kaduna | 0 | 0 | 0 | 0 | 0 | 15 | 2 | 17 |
| 20 | Ebonyi | 0 | 0 | 0 | 1 | 0 | 12 | 1 | 14 |
| 21 | Benue | 2 | 0 | 0 | 0 | 0 | 10 | 0 | 12 |
| 22 | Borno | 0 | 0 | 0 | 0 | 0 | 11 | 2 | 13 |
| 23 | Enugu | 1 | 2 | 1 | 0 | 0 | 4 | 4 | 12 |
| 24 | Katsina | 0 | 0 | 0 | 0 | 0 | 8 | 1 | 9 |
| 25 | Taraba | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 7 |

| | | | | | | | | | |
|----|--------------------|-----------|-----------|-----------|----------|-----------|------------|-----------|-------------|
| 26 | Kano | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 7 |
| 27 | Gombe | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 6 |
| 28 | Kogi | 0 | 0 | 0 | 0 | 0 | 5 | 2 | 7 |
| 29 | Osun | 0 | 0 | 0 | 0 | 0 | 5 | 1 | 6 |
| 30 | Ekiti | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 4 |
| 31 | Niger | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 |
| 32 | Kebbi | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 3 |
| 33 | Bauchi | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| 34 | Zamfara | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| 35 | Yobe | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| 36 | Jigawa | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| | Grand Total | 88 | 49 | 47 | 8 | 34 | 762 | 97 | 1085 |

Response activities

| Pillar | Activities to date | Next steps |
|---------------------|--|---|
| Coordination | <ul style="list-style-type: none"> Facilitating the smooth running of the weekly Mpox technical working group meetings Providing offsite subnational support to resolve issues in reporting States | <ul style="list-style-type: none"> Follow-up implementation of the approved Incident Action plan activities in collaboration with other pillars |
| Surveillance | <ul style="list-style-type: none"> Twenty one(21) suspected Mpox cases were reported from 11 States Two confirmed cases were recorded | <ul style="list-style-type: none"> Continue to support all State Surveillance teams to ensure on SORMAS |
| Laboratory | <ul style="list-style-type: none"> The sample positivity rate for Mpox is 10% and 33% for Varicella-Zoster Virus (VZV) | <ul style="list-style-type: none"> Continue to support effective sample management and transportation to the NRL from health facilities across the country |

Notes on this report.

Data Source

Information for this disease was case-based data retrieved from the National Mpox Emergency Operations Centre.

Case definitions

Suspected case

- An acute illness with fever $>38.3^{\circ}\text{C}$, intense headache, lymphadenopathy, back pain, myalgia, and intense asthenia followed one to three days later by a progressively developing rash often beginning on the face (most dense) and then spreading elsewhere on the body, including soles of feet and palms of the hand.

Probable case

- A case that meets the clinical case definition is not laboratory-confirmed but has an epidemiological link to a confirmed case.

Confirmed case.

- A clinically compatible case that is laboratory confirmed

Contact

- Any person who has been in direct or indirect contact with a confirmed case since the onset of symptoms, i.e., contact with skin lesions, oral secretions, urine, faeces, vomitus, blood, sexual contact, sharing a common space (anyone who has been in proximity with or without physical contact with a confirmed case)

Calculations

- Case Fatality Rate (CFR) for this disease is reported for confirmed cases only.